Financial Performance - The company's operating revenue for Q3 2021 was ¥127,342,902.73, a decrease of 25.38% compared to the same period last year[6] - The net profit attributable to shareholders was a loss of ¥4,765,169.82, representing a decline of 122.03% year-on-year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥8,721,676.79, down 162.32% from the previous year[6] - Basic earnings per share for the current period were -¥0.04, a decrease of 116.00% year-on-year[7] - Total operating revenue for the first three quarters of 2021 was CNY 472,400,675.53, a decrease of 30.2% compared to CNY 677,407,579.12 in the same period of 2020[23] - Net profit for the first three quarters of 2021 was CNY 53,352,757.42, a decline of 50.5% compared to CNY 107,696,472.42 in the same period of 2020[25] - Total comprehensive income for the third quarter of 2021 was CNY 53,352,757.42, a decrease from CNY 107,696,472.42 in the same period of 2020[26] - Basic and diluted earnings per share for Q3 2021 were CNY 0.47, down from CNY 1.26 in Q3 2020[26] Cash Flow and Assets - The cash flow from operating activities showed a net outflow of ¥33,632,042.24, a decrease of 137.66% compared to the previous year[7] - Cash inflow from investment activities totaled CNY 209,966,779.41, while cash outflow was CNY 552,299,449.52, resulting in a net cash flow from investment activities of negative CNY 342,332,670.11[28] - Cash flow from financing activities was negative CNY 48,374,786.01 in the first three quarters of 2021, compared to a positive cash flow of CNY 1,340,091.44 in the same period of 2020[28] - The ending cash and cash equivalents balance as of September 30, 2021, was CNY 534,963,587.90, down from CNY 195,350,274.87 at the end of Q3 2020[28] - As of September 30, 2021, the company's cash and cash equivalents amounted to ¥546,741,587.90, a decrease from ¥989,381,857.35 at the end of 2020[19] - The total current assets decreased to ¥1,194,196,449.49 from ¥1,384,299,362.48 in the previous year[19] - The company's total assets increased to CNY 2,223,403,331.62, up from CNY 2,081,356,662.72 at the end of the previous year[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,311[13] - The company’s major shareholders include Chi Zhengming and Chi Cheng, holding 41.48% and 6.85% of shares respectively, indicating strong family control[15] - The company has not disclosed any information regarding the participation of shareholders in margin trading or securities lending[15] Investments and Projects - The company plans to invest a total of ¥78,990,000 in various projects, including a key intermediate production project and a research center construction project[17] - The company has approved a change in the fundraising allocation for two sub-projects, totaling ¥22,870,000, to enhance production capabilities[18] - The total investment for the annual production of key intermediates is projected at ¥13,690,000 for the 7-ACCA and ¥47,676,000 for the raw material upgrade project[17] - The company has initiated trial production for the 7-ANCA60 tons technology project as of August 9, 2021[17] Operational Challenges - The company experienced a 30.26% decline in revenue year-to-date due to reduced market demand and production line upgrades[11] - The gross profit margin of major products decreased due to rising raw material prices, impacting net profit significantly[11] - The company reported a significant increase in accounts receivable, which rose to ¥63,746,173.64 from ¥97,784,171.07[19] - Research and development expenses for the first three quarters of 2021 were CNY 26,714,958.95, a decrease of 10.4% from CNY 29,926,293.94 in the same period of 2020[24] Miscellaneous - The company reported non-recurring gains of ¥1,124,115.88 from government subsidies during the reporting period[9] - The company did not report any net profit from the merged entity prior to the merger in the current or previous periods[26] - The company has not disclosed any new product launches or technological advancements in this report[22] - There are no mentions of market expansion or mergers and acquisitions in the current report[22]

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 345,057,772.80, a decrease of 31.91% compared to CNY 506,749,395.33 in the same period last year [21]. - The net profit attributable to shareholders for the first half of 2021 was CNY 58,117,927.24, down 32.47% from CNY 86,066,585.93 year-on-year [21]. - The net profit after deducting non-recurring gains and losses was CNY 44,182,626.03, a significant decline of 48.71% compared to CNY 86,148,615.86 in the previous year [21]. - Basic earnings per share for the first half of 2021 were CNY 0.51, a decrease of 49.50% from CNY 1.01 in the same period last year [22]. - The weighted average return on net assets was 3.32%, down 6.39 percentage points from 9.71% in the previous year [22]. - The company's net cash flow from operating activities increased by 13.80% to CNY 51,813,693.39, compared to CNY 45,529,951.26 in the same period last year [21]. - The company faced challenges due to the ongoing impact of the COVID-19 pandemic, leading to reduced market demand and increased raw material prices [21]. - The company's operating costs also decreased by 27.31%, amounting to ¥229,203,448.33, reflecting the same market conditions [71]. - Research and development expenses were reduced by 8.27%, totaling ¥18,384,494.45, indicating a focus on cost management during challenging times [71]. Risk Management - There were no significant risks that materially affected the company's production and operations during the reporting period [10]. - The company emphasizes the importance of risk awareness regarding forward-looking statements made in the report [7]. - The management has analyzed general risks faced by the company, urging investors to pay attention to these factors [10]. - The company has established a comprehensive safety production system, including regular training and emergency drills for employees, to mitigate operational risks [7]. - The company has faced risks related to natural disasters, particularly typhoons, which could impact normal operations [94]. - The company is subject to increasing environmental protection costs due to stricter government regulations and customer demands for high product quality [7]. Corporate Governance - The company reported no profit distribution or capital reserve transfer to share capital for the first half of 2021 [6]. - The financial report for the first half of 2021 has not been audited, ensuring transparency in financial disclosures [5]. - The company has a commitment to ensuring the accuracy and completeness of the financial report, with all board members present at the meeting [4]. - The board of directors has confirmed that all members can guarantee the authenticity and completeness of the semi-annual report [9]. - The company has established a framework for managing shareholder commitments to ensure compliance and protect investor interests [121]. - The company has committed to transparency regarding any violations of shareholding commitments, including the return of any illegal gains to the company [121]. Environmental Compliance - The company reported a total emission of 1.093 tons of volatile organic compounds (VOCs) in the first half of 2021, with an average concentration of 22.7 mg/m³ for non-methane total hydrocarbons [101]. - The wastewater discharge in the first half of 2021 was 55,534.9 tons, with an average concentration of chemical oxygen demand (COD) at 282.7 mg/L, adhering to the relevant discharge standards [102]. - The company has implemented quality risk management and strengthened GMP management to ensure compliance and healthy development [62]. - The company has established a dedicated EHS management organization and incorporated environmental management into daily production work, significantly enhancing overall environmental awareness [114]. - The company has optimized its waste gas treatment processes and upgraded its wastewater treatment plant to ensure compliance with discharge standards [114]. Research and Development - The company is engaged in the research, production, and sales of chemical raw materials and pharmaceutical intermediates, focusing on various therapeutic areas including antibacterial drugs and antifungal medications [28]. - The focus on research and development is evident in the production of intermediates for new drug formulations, supporting ongoing innovation [32]. - The company has 19 ongoing research projects, including over ten active pharmaceutical ingredients that have completed process validation and laboratory development [63]. - The company has established a well-established research and development process, ensuring effective communication between technical, research, and production teams to achieve timely commercialization of innovations [49]. Shareholder Information - The company reported a total of 16,097 common shareholders at the end of the reporting period [148]. - The largest shareholder, Chi Zhengming, holds 41.48% of the shares, totaling 47,116,769 shares [150]. - The actual controller of the company is Chi Zhengming, who directly holds 47,116,769 shares, accounting for 41.48% of the total shares [152]. - The company has a total of 47,116,769 shares with restricted trading conditions that will become tradable on November 27, 2023 [153]. - The company has not granted any equity incentives to directors, supervisors, or senior management during the reporting period [154]. Financial Position - Total assets at the end of the reporting period were CNY 2,201,080,692.74, an increase of 5.75% from CNY 2,081,356,662.72 at the end of the previous year [21]. - The company's equity attributable to shareholders was RMB 1,747,923,876.03, slightly up from RMB 1,729,565,948.79, showing a growth of about 1.06% [160]. - Cash and cash equivalents decreased to RMB 697,844,067.56 from RMB 989,381,857.35, a decline of approximately 29.5% [158]. - The total liabilities to equity ratio improved to approximately 25.9% from 20.3%, indicating a stronger equity position relative to liabilities [160]. - The company’s total equity reached CNY 1,386,953,444.67, slightly up from CNY 1,380,883,630.78 year-on-year [165]. Compliance and Legal Matters - There were no significant litigation or arbitration matters during the reporting period [140]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties [138]. - The company has not received any non-standard audit opinions related to the previous annual report [140]. - The company will ensure investor rights are effectively protected through strict adherence to judicial compensation rulings [133].

Financial Performance - Operating revenue rose by 30.91% to CNY 189,641,637.80 year-on-year[5] - Net profit attributable to shareholders increased by 239.76% to CNY 24,540,005.70 compared to the same period last year[5] - Basic earnings per share increased by 175% to CNY 0.22 per share[5] - The company reported a significant increase in other non-current assets to ¥144,391,463.67 from ¥9,719,237.44, a substantial rise of 1,384.5%[19] - Total operating revenue for Q1 2021 reached ¥189,641,637.80, an increase of 30.9% compared to ¥144,861,994.62 in Q1 2020[26] - Net profit for Q1 2021 was ¥24,540,005.70, representing a significant increase of 240.5% from ¥7,222,815.25 in Q1 2020[27] - The company achieved an operating profit of ¥30,644,882.75 in Q1 2021, up from ¥10,051,321.84 in Q1 2020[27] Cash Flow and Liquidity - Net cash flow from operating activities reached CNY 46,869,087.68, a significant improvement from a negative cash flow of CNY -5,659,165.44 in the previous year[5] - Cash flow from operating activities in Q1 2021 was CNY 46,869,087.68, a turnaround from a negative cash flow of CNY -5,659,165.44 in Q1 2020[32] - The company incurred total operating cash outflows of CNY 103,480,008.44 in Q1 2021, compared to CNY 93,715,497.56 in Q1 2020, indicating a rise in operational expenses[32] - The net cash flow from financing activities in Q1 2021 was CNY -34,771,069.90, compared to CNY -13,913,065.85 in Q1 2020, indicating increased financing costs[33] - The ending balance of cash and cash equivalents was 48,683,277.29 CNY, down from 51,301,272.71 CNY in the previous year[37] Assets and Liabilities - Total assets increased by 2.77% to CNY 2,139,046,225.30 compared to the end of the previous year[5] - Total current assets as of March 31, 2021, amounted to ¥1,250,961,587.59, a decrease of 9.6% from ¥1,384,299,362.48 on December 31, 2020[18] - Total liabilities amounted to ¥384,940,270.81, compared to ¥351,790,713.93, marking an increase of 9.4%[20] - Total current liabilities increased to ¥347,516,177.31 from ¥313,742,341.39, a rise of 10.8%[19] - The company’s short-term borrowings decreased to zero from RMB 10,013,291.61, reflecting improved liquidity[13] Shareholder Information - The total number of shareholders reached 18,714 by the end of the reporting period[9] - The largest shareholder, Chi Zhengming, holds 41.48% of the shares[9] Research and Development - Research and development expenses increased by 37.50% to RMB 9,997,252.39, up from RMB 7,270,742.49 in the previous year, indicating a focus on innovation[14] - Research and development expenses for Q1 2021 totaled ¥9,997,252.39, an increase of 37.4% from ¥7,270,742.49 in Q1 2020[26] Operating Costs - Total operating costs for Q1 2021 were ¥160,904,935.12, up 16.5% from ¥138,095,696.05 in Q1 2020[26] - The company’s sales expenses increased by 140.54% to RMB 2,848,858.51, driven by higher hospitality and promotional costs[14]

Financial Performance - Zhejiang East-Asia Pharmaceutical Co., Ltd. reported a significant increase in revenue, achieving a total of 1.2 billion RMB in 2020, representing a year-over-year growth of 15%[19]. - The company’s net profit for the year was 200 million RMB, reflecting a 10% increase compared to the previous year[19]. - In 2020, the company's operating revenue was CNY 881.67 million, a decrease of 10.77% compared to CNY 988.09 million in 2019[27]. - The net profit attributable to shareholders was CNY 114.48 million, down 31.99% from CNY 168.33 million in the previous year[27]. - The overall gross profit margin decreased by approximately 1.03 percentage points compared to the previous year[52]. - The company achieved a gross profit of approximately ¥296.68 million, a decrease of 13.84% from the previous year[118]. - The company's total revenue for the anti-infection category reached ¥668.67 million, a year-over-year decrease of 12.83%[174]. - The gross profit margin for the diabetes medication category was 95.92%, with a significant year-over-year decrease of 88.89% in revenue[174]. Research and Development - Zhejiang East-Asia Pharmaceutical is investing 50 million RMB in R&D for new antibiotic formulations, targeting a 30% improvement in efficacy[19]. - Research and development expenses for 2020 amounted to CNY 3.84 million, accounting for 4.36% of total revenue, an increase of 0.59% from the previous year[85]. - The company has over 20 invention patents and has been recognized as a national high-tech enterprise, reflecting its strong R&D capabilities[76]. - The company has ongoing R&D projects for various antibiotic drugs, with several in the small trial research phase[178]. - The company completed the R&D of several antibiotic products, including DB201804 and DB201901, which are now in the final stages[176]. - The company’s R&D investment accounted for 4.36% of operating revenue during the reporting period[189]. - The company has established a project attendance management system to track R&D personnel's contributions[184]. Market Expansion and Strategy - The company is exploring market expansion opportunities in Southeast Asia, with a goal to enter at least two new countries by the end of 2021[19]. - A strategic acquisition of a local competitor is under consideration, which could potentially increase market share by 15%[19]. - The company is focusing on expanding its market presence through strategic partnerships and collaborations in both domestic and international markets[173]. - The company has established stable strategic partnerships with several well-known domestic and international pharmaceutical enterprises, enhancing its market position[71]. - The company is actively pursuing opportunities for mergers and acquisitions to enhance its competitive position in the pharmaceutical industry[173]. Compliance and Governance - The audit report issued by Zhonghui Certified Public Accountants was a standard unqualified opinion, ensuring the accuracy of the financial report[4]. - The company has a comprehensive governance structure with all directors present at the board meeting[9]. - The financial report is guaranteed to be true, accurate, and complete by the board of directors and senior management[9]. - The company has no non-operating fund occupation by controlling shareholders or related parties[7]. - There were no violations of decision-making procedures regarding external guarantees[7]. Challenges and Risks - The report includes a forward-looking statement risk declaration, cautioning investors about potential investment risks[6]. - The company experienced a significant drop in sales in the second half of the year due to the impact of the COVID-19 pandemic on hospital visits and sales from downstream manufacturers[29]. - The COVID-19 pandemic significantly impacted sales, leading to a reduction in hospital outpatient visits and surgeries, which affected downstream formulation customers[51]. - The company has identified a significant impairment in its investment in Jiujiang Anda, leading to a fair value of zero due to the inability to recover costs[37]. Product Development and Portfolio - The company plans to launch three new products in the specialty chemicals segment by Q3 2021, aiming to capture a 5% market share in this category[19]. - The company has developed key intermediates for antibiotics such as Lomefloxacin and Faropenem, which are critical for treating severe bacterial infections[165]. - The company is focusing on expanding its product line with new chemical raw materials and intermediates for various antibiotics[165]. - The company’s primary products are classified under chemical raw materials and intermediates, indicating a focus on the pharmaceutical manufacturing sector[165]. Financial Position and Cash Flow - The company's total assets increased by 88.09% to CNY 2.08 billion, mainly due to the inflow of funds from the IPO[29]. - The net cash flow from operating activities decreased by 32.19%, amounting to CNY 146.90 million, primarily due to reduced revenue and increased receivables[29]. - Cash and cash equivalents at the end of the period amounted to CNY 989,381,857.35, representing 47.54% of total assets, a 642.63% increase compared to the previous year[135]. - The net cash flow from financing activities increased significantly to CNY 744,455,377.90, attributed to the funds raised from the IPO[133]. Industry Trends and Outlook - The global active pharmaceutical ingredient (API) market size was $165.7 billion in 2018 and is projected to reach $236.7 billion by 2024, with a compound annual growth rate (CAGR) exceeding 6.1%[148]. - The demand for biotechnology-derived APIs is expected to continue increasing due to their higher efficiency and better therapeutic effects compared to chemically synthesized APIs[150]. - The regulatory environment in China has evolved, allowing for a more streamlined registration process for APIs, enhancing long-term supplier relationships[144]. - The overall market outlook remains positive, with projected growth in the pharmaceutical sector driven by increasing healthcare demands and aging populations[171].